Tags : reSET-O

Sandoz Receives FDA’s Clearance for reSET-O, a Medical Mobile App

Shots: The approval is based on trial results assessing reSET-O in 170 patients receiving either treatment-as-usual (TAU) + standard clinician interactions + buprenorphine or reSET-O + standard clinician interactions + buprenorphine for 12 wks. The study demonstrated improved and increase rates of retention time with efficacy results in patients with OUD reSET-O is a FDA […]Read More